Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma - Wikidata - wikimedia - TriplyDB

Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma

Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma

http://www.wikidata.org/entity/Q27851513

about

sameAs

Monoclonal antibodies.A cytomorphological and immunohistochemical profile of aggressive B-cell lymphoma: high clinical impact of a cumulative immunohistochemical outcome predictor score A 61-year-old man with dyspepsia and weight loss Role of apoptosis in disease Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review CIViC database Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-cell lymphoma.Clinical implications of SPRR1A expression in diffuse large B-cell lymphomas: a prospective, observational study.EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer.Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy.B cells with high side scatter parameter by flow cytometry correlate with inferior survival in diffuse large B-cell lymphoma Inhibition of human diffuse large B-cell lymphoma growth by JC polyomavirus-like particles delivering a suicide gene Detection of BCL2 rearrangements in follicular lymphoma Peeling off the hidden genetic heterogeneities of cancers based on disease-relevant functional modules.Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era.The essential role of evasion from cell death in cancer.Building an outcome predictor model for diffuse large B-cell lymphoma.Genotypic and phenotypic differences between nodal and extranodal diffuse large B-Cell lymphomas.High frequency of germinal centre derivation in diffuse large B cell lymphoma from Asian patients Prognostic value of immunohistochemical biomarkers at different cut-off values in patients with diffuse large B-cell lymphoma treated with CHOP chemotherapy.Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study Detection of the bcl-2 t(14;18) translocation and proto-oncogene expression in primary intraocular lymphoma.Genetic lesions in diffuse large B-cell lymphomas Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells Non-Hodgkin lymphoma and GIST: molecular pathways and clinical expressions.Differential role of BCL2 in molecular subtypes of diffuse large B-cell lymphoma.Bcl-2-family proteins and hematologic malignancies: history and future prospects.Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.Delivery of intracellular-acting biologics in pro-apoptotic therapies.p27KIP1 is abnormally expressed in Diffuse Large B-cell Lymphomas and is associated with an adverse clinical outcome.Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast Nodal aggressive B-cell lymphomas: a diagnostic approach Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma.Cutaneous presentation of Double Hit Lymphoma: A Case Report With Review of the Literature.SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status.Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.Role of peroxisome proliferator-activated receptor gamma and its ligands in the treatment of hematological malignancies

P2860

ecb886d3108767e84b568f4805243db521e0aa24

P248

Q24535231-E930F2CA-618C-4216-A570-917A50911EED Q24653343-E7BB7BFB-1E67-4B75-B9E3-6272F2E48731 Q24813742-43041C7B-321D-4C7D-B9B6-71BA92885577 Q26865637-DA7D00CC-1EE5-46CD-B875-FB7862CA3209 Q27304386-A70E8E2B-AF43-4A59-935D-4B68BF368A20 Q27612411-E7CBF226-C18F-4831-8EEF-39CB855F1824 Q33392920-B7127F1E-6D6F-4F55-93E8-FD0A0A383E18 Q33700531-5904DED6-4049-4E41-A05A-27CE99DF9AC1 Q33712958-3EDA10A6-B3CB-49A3-826C-414D1BF30F65 Q33793142-2ADB4CE6-01D5-4894-999D-A5E0138FC453 Q33846801-EA77DA2C-C6AB-4DBB-BD4F-617F8E8CAAF7 Q34270046-976FF127-222D-40B7-B0A1-025870E8B8AF Q34459849-8F803990-D459-4F68-B74B-8CF3661E33BA Q34560953-99CF9D51-C696-45B4-BE5F-B19D5F8BEDEE Q34809541-22792A9D-F801-48A0-96B1-DBAEBCD4E66A Q34882773-60CB337F-4D79-423D-9094-1BD0525E8D85 Q35083049-CFEA6792-BE6C-46DA-BE93-78C4DE20B4FF Q35083387-F91DA9E0-334C-4648-9B34-1B91490139CD Q35440675-A576E5C1-4299-409F-B285-D776912D6682 Q35588996-25B3B041-579C-4AD0-B49F-E0BF0A7B0FAA Q35590607-96591CE8-E5DD-415A-AA7B-9502C4B47764 Q35746987-C67A57AF-7D4A-4FF9-98B2-B65C9CF86075 Q35847673-4CABA11A-E02E-422F-8229-1D325DDB5BF6 Q35849663-7A30511F-47DF-4024-9E87-7F462DFD528E Q35933199-2884BE6E-61B8-43D5-9B30-8036E2AB1A0B Q35974341-F5A57877-DD04-4AAD-B121-277C75D6CB5B Q36384652-96C32EAE-FE84-4436-ADDC-E2EE057CAD95 Q36474669-6E1912E8-78C8-4139-A826-83026DCF620E Q36493374-F3214BF8-879D-4635-AA0C-4CFFC2703DC2 Q36508817-147EDEFA-52F8-4334-8D66-E5A8C04B5B7C Q36579119-49B3751E-CF17-4D6D-8D5F-057D3F6A2E72 Q36588920-31E2E59D-1AE1-44E1-9C44-91E7E4AF348B Q36620425-4BF77282-9250-44AC-8A67-F1C78458F3A3 Q36678684-32C14C6D-B149-4C68-84A4-0EE5A4CBCD45 Q36763463-8A4D3593-3FF7-4595-A91A-520639021C4C Q36776444-CC233967-CC98-4925-B721-A2B9329DEDEE Q36799405-32115EA8-8A57-4A12-AD84-ACAAE9D762C6 Q37119032-D211F00F-449A-48BB-949E-47B40F3683E3 Q37178611-A5308C3A-92CE-4DB9-9727-DC1943A60702 Q37182794-2097852A-ED86-4AE1-AFA0-E11A3EB89E1B

P2860

Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma

http://www.wikidata.org/entity/Q27851513

description

1997 nî lūn-bûn

@nan

1997 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

1997 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

1997年の論文

@ja

1997年論文

@yue

1997年論文

@zh-hant

1997年論文

@zh-hk

1997年論文

@zh-mo

1997年論文

@zh-tw

1997年论文

@wuu

name

Prognostic significance of Bcl ...... ressive non-Hodgkin's lymphoma

@ast

Prognostic significance of Bcl ...... ressive non-Hodgkin's lymphoma

@en

Prognostic significance of Bcl ...... ressive non-Hodgkin's lymphoma

@nl

type

label

Prognostic significance of Bcl ...... ressive non-Hodgkin's lymphoma

@ast

Prognostic significance of Bcl ...... ressive non-Hodgkin's lymphoma

@en

Prognostic significance of Bcl ...... ressive non-Hodgkin's lymphoma

@nl

prefLabel

Prognostic significance of Bcl ...... ressive non-Hodgkin's lymphoma

@ast

Prognostic significance of Bcl ...... ressive non-Hodgkin's lymphoma

@en

Prognostic significance of Bcl ...... ressive non-Hodgkin's lymphoma

@nl

P1433

Q27851513-7D73B477-0869-4CAB-A782-7B2131B50D82

P1476

Q27851513-AC9AC7EB-F9BD-4DC3-87F1-D01595A88D14

P2093

Q27851513-0C4F2711-AA00-4202-A4ED-E8BABD21819F

Q27851513-1B45F05B-26AD-4BC8-968F-7CF00210F51C

Q27851513-5E8C87D6-425B-448F-8297-B019D8969AEB

Q27851513-7344682D-0CD5-43EB-B676-9CE94D8D5CC0

Q27851513-74684E04-59D8-4673-9387-0B6467243215

Q27851513-93CB422F-EDEB-432A-81EE-37A21F694625

Q27851513-B8D8163F-1892-4D9F-9B37-4D212FF30325

Q27851513-C9D3C9DB-F0C8-481B-A023-956E78EAEC60

Q27851513-D491D46C-E52F-43DA-914D-8794E604D947

Q27851513-D9E2749E-9FDA-46F8-BBBE-7F2CFAA61848

P304

Q27851513-41FBF0F9-5C09-457E-93E1-0E1CFC281F00

P31

Q27851513-286FE638-BC01-42B3-AD87-1FA203487FAA

P3181

Q27851513-E8684535-BF9A-497B-9887-45A511BD5E61

P407

Q27851513-2C26AACD-1FF6-4806-8A69-A0A2D1865802

P433

Q27851513-7D9BAD5E-D825-478C-8D69-30BEDBE6CD15

P478

Q27851513-A59B8D90-216D-4CD6-8230-DE6957FC0A9C

P577

Q27851513-0DB775EC-F440-4BA1-8038-5FC50F7E1A38

P698

Q27851513-563F166F-4B1A-490E-9F88-77E3853704F8

P3181

P1433

P1476

Prognostic significance of Bcl ...... ressive non-Hodgkin's lymphoma

@en

P2093

Adomat SA

http://www.w3.org/2001/XMLSchema#string

Coldman AJ

http://www.w3.org/2001/XMLSchema#string

Connors JM

http://www.w3.org/2001/XMLSchema#string

Gascoyne RD

http://www.w3.org/2001/XMLSchema#string

Horsman DE

http://www.w3.org/2001/XMLSchema#string

Hoskins P

http://www.w3.org/2001/XMLSchema#string

Krajewska M

http://www.w3.org/2001/XMLSchema#string

Krajewski S

http://www.w3.org/2001/XMLSchema#string

O'Reilly SE

http://www.w3.org/2001/XMLSchema#string

Reed JC

http://www.w3.org/2001/XMLSchema#string

P304

244-251

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2404515

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

90

http://www.w3.org/2001/XMLSchema#string

P577

1997-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9207459

http://www.w3.org/2001/XMLSchema#string